Professor of Medicine Evan Yu and Associate Professor Tanya Dorff provide their thoughts and views on combination, sequential and immuno-oncology therapies in mCRPC (Metastatic Castration-Resistant Prostate Cancer)


The background of combination immunotherapy

In this video and accompanying slides Prof. Evan Yu and Prof. Tanya Dorff address how to treat metastatic castration-resistant prostate cancer (mCRPC) using combination and sequential immuno-oncology therapies. Prof. Yu discusses immuno-oncology in prostate cancer and details the need for combination therapies. Explored are current prostate cancer immunotherapy treatments such as Sipuleucel-T, and other IO treatments approved in other cancers and being investigated in prostate cancer. These include PD1 antibodies and PD-L1 antibodies. Prof. Yu describes a study examining the effect of enzalutamide treatment on PD-L1/2 tumor staining, and how this may be relevant for treating subpopulations of patients. Presented are data using the PD1 binding antibody, pembrolizumab, to treat PD-L1 positive prostate cancer.

The influence of mutational profile on immunotherapy response

Further discussion focuses on the prediction of solid tumour responsiveness to immunotherapy based on the mutational profile. Examined are mismatch repair with microsatellite instability (MSI) and DNA repair gene alterations in prostate cancer as a consideration for immunotherapy treatment. Also covered are the KEYNOTE 365 clinical trial which examines pembrolizumab in combination therapies with a number of different therapies in mCRPC, and ongoing trials in immunotherapy with focus on combination therapies. The slide-set concludes with a look at immunotherapy for the non-inflamed phenotype and how that can be addressed with immune priming strategies. Watch the video and download the slides to benefit from this practical guidance for medical oncologists.

Dr. Evan Y. Yu is a medical oncologist specializing in genitourinary malignancies, specifically prostate, bladder and testicular cancer treatment and research. His research focuses on testing the next wave of novel molecular targeted therapies and immunotherapy techniques, with a complementary focus on imaging biomarkers. He is Section Head, Medical Oncology in the Clinical Research Division at Fred Hutch Cancer Center. He also serves as the Medical Director for Clinical Research for the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium. He is a Professor at the University of Washington and Fred Hutch Cancer Center. He is principal investigator for the National Cancer Trials Network Lead Academic Performance Site (LAPS) Grant, SWOG, and ECOG/ACRIN. Dr. Yu is also the core director for the Pacific Northwest Prostate Cancer SPORE and co-PI of the DoD Prostate Cancer Clinical Trials Consortium for his institution. He graduated Alpha Omega Alpha from the University of Washington School of Medicine. Previously, he served as a Hematology/Oncology Fellowship Program Director for a decade at Fred Hutch. He has regularly been voted a “Top Doctor” by Castle Connolly, Seattle Magazine, and Seattle Met magazine. He has served for many years on the National Cancer Institute Genitourinary Cancers Steering Committee and is currently the co-chair for the National Cancer Institute Prostate Cancer Task Force. Dr. Yu has held various leadership/committee roles within ASCO, AACR, and also serves as a senior editor for Clinical Cancer Research and Uro-Today.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

ipcv Interactive Patient Case Video (IPCV)

Episode

1

of 1

episode
Oncology 
Shared decision-making for prostate cancer patients

Early treatment intensification with a PARPi plus ARPI combination

Experts
Prof. Gunhild von Amsberg
Endorsed by
  • clock 25 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
micro-learning Micro learning - Video, slides and more

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Oct 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
animated-video Animated Video

Episode

2

of 2

episode
Oncology 
Clinical implementation of testing and PARPis in combination with NHAs

Episode 2: Clinical implementation of testing and PARP inhibitors in combination with NHAs

Experts
Dr Andrew J. Armstrong
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
animated-video Animated Video

Episode

1

of 2

episode
Oncology 
Clinical implementation of testing and PARPi as monotherapy

Episode 1: Clinical implementation of testing and PARPi monotherapy

Experts
Dr Neal Shore
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Video podcast
Oncology 
Which mCSPC patients benefit from early treatment intensification?

A podcast from GU oncology experts

Experts
Assoc. Prof. Shilpa Gupta, Dr Fabio Schutz
  • download Downloadable
    Resources
  • clock 22 MIN
  • calendar Mar 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer
conference-update Conference update

Episode

4

of 4

episode
Oncology 
Highlights from ESMO 2026

Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers

Experts
Dr Elizabeth Smyth, Dr Yelena Janjigian, Assoc. Prof. Gerald Prager, Prof. Hong Jae Chon, Assoc. Prof. Lorenza Rimassa, Dr Tom Newsom-Davis, Dr Louise Lim, Dr Komal Jhaveri, Dr Roberto Iacovelli
Endorsed by
  • download Downloadable
    Resources
  • clock 9 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education